1. Pezaro S, Brock I, Buckley M, Callaway S, Demirdas S, et al. (2024) Management of childbearing with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders: A scoping review and expert co-creation of evidence-based clinical guidelines. PLOS ONE 19(5): e0302401. https://doi.org/10.1371/journal.pone.0
  2. Pizano J., Zingman A., Brock I., Maitland A., Schubart J., Francomano C., Nutritional Markers of Histamine Intolerance in Ehlers-Danlos Syndromes. Genetics in Medicine Open, Volume 1, Issue 1, Supplement 100197, 2023
  3. Brock I., Maitland A., Mast Cells and COVID-19: A Case Report Implicating a Role of Mast Cell Activation in the Prevention and Treatment of COVID-19. J Vaccines Vaccin. 2021. S12:00 DOI: 10.35248/2157-7560.21.s12.005
  4. Brock I., Prendergast W., Maitland A., Mast cell activation disease and immunoglobulin deficiency in patients with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorder. Am J Med Genet C Semin Med Genet. 2021. doi:10.1002/ajmg.c.31940
  5. Brock I., Eng N., Maitland A., Adult-onset mast cell activation syndrome following scombroid poisoning: a case report and review of the literature. J Med Case Rep. 2021. doi:10.1186/s13256-021-03190-w
  6. Hamonet C., Brock I., Hamonet-Dewez M., Brissot R., Local Multiple Injections of Lidocaine as a Very Efficient Treatment of Intractable Pains in Ehlers-Danlos Disease. The Dysproprioception Hypothesis. EC Anaesthesia. 2019;5(9):290-296
  7. Hamonet, C., Gompel, A., Baeza-Velasco, Ducret, L., Metlaine, A., Ehlers-Danlos Syndrome ( EDS )-Contribution to Clinical Diagnosis-A Prospective Study of 853 Patients. EC Neurology 2018;10.6
  8. Chopra P., Tinkle B., Hamonet C., Brock I., Gompel A., Bulbena A., Francomano C., Pain management in the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):212-219. doi:10.1002/ajmg.c.31554
  9. Hamonet C., Brock I., Pommeret S., et al. Syndrome d’Ehlers-Danlos (SED) Type III (Hypermobile): Validation d’une Échelle Clinique Somatosensorielle (ECSS-62), à Propos de 626 Cas.; 2016. https://doi.org/10.1016/S0001-...
  10. Hamonet C., Ducret L., Marié-Tanay C., Brock I., Dystonia in the joint hypermobility syndrome (a.k.a. Ehlers-Danlos syndrome, hypermobility type). SOJ Neurol, 3(1), 1-3. 2016. DOI: 10.15226/2374-6858/3/1/00123
  11.  Hamonet C, Amoretti R, Brock I, Fredy D, Baeza-Velasco C, Nourissat G. Hypermobilité, syndrome d’Ehlers-Danlos (SED) et performances sportives. Journal de Traumatologie du Sport. 2016;33(2):80-87. doi:10.1016/j.jts.2016.03.001
  12. C. Hamonet, M. Vienne, C. Leroux, M.P. Letinaud, J. Paumier, B. Dehecq, A. Metlaine, I. Brock, F.M. Bird, Manifestations respiratoires dans le syndrome d’Ehlers-Danlos (SED). Nouveaux apports thérapeutiques, Journal de Réadaptation Médicale : Pratique et Formation en Médecine Physique et de Réadaptation, Volume 36, Issue 1, 2016, Pages 56-61, https://doi.org/10.1016/j.jrm....
  13. Hamonet C, Brock I. Joint mobility and Ehlers-Danlos syndrome, (EDS) new data based on 232 cases. J Arthritis. 2015;04(02). doi:10.4172/2167-7921.1000148
  14. Hamonet C, Gompel A, Mazaltarine G, Brock I, Baeza-Velasco C, et al. Ehlers-Danlos Syndrome or Disease? J Syndromes. 2015;2(1): 5 DOI: 10.13188/2380-6036.1000005
  15. C. Hamonet, I. Brock, Un droit spécifique du handicap ou bien : les droits de tous pour les personnes en situation de handicap?, Journal de Réadaptation Médicale : Pratique et Formation en Médecine Physique et de Réadaptation, Volume 35, Issue 2, 2015, Pages 51-53, https://doi.org/10.1016/j.jrm....
  16. 2017 EDS International Classification - The Ehlers Danlos Society
  17. Tinkle B, Castori M, Berglund B, Cohen H, Grahame R, Kazkaz H, Levy H. 2017. Hypermobile Ehlers–Danlos syndrome (a.k.a. Ehlers–Danlos syndrome Type III and Ehlers–Danlos syndrome hypermobility type) : Clinical description and natural history. Am J Med Genet Part C Semin Med Genet 175C:48–69.
  18. Smith C. 2017. Understanding Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorder. Redcliff-House Publications 2017.
  19. The Ehlers-Danlos Society. EDNF becomes The Ehlers-Danlos Society. Retrieved fromhttps://www.ehlers-danlos.com/ednf-becomes-the-ehlers-danlos-society/
  20. Tennant F. 2015. Managing Intractable Pain in Ehlers-Danlos. Retrieved fromhttps://www.youtube.com/watch?v=pLw29ndmLcA
  21. Dupuy EG, Leconte P, Vlamynck E, Sultan A, Chesneau C, Denise P, Besnard S, Bienvenu B, Decker LM. 2017. Ehlers-Danlos Syndrome, Hypermobility Type : Impact of Somatosensory Orthoses on Postural Control (A Pilot Study). Front. Hum. Neurosci. 11:283. Doi : 10.3389/fnhum.2017.00283
  22. Hamonet C, Vlamynck E, Haidar R, Bonny C, Mazaltarine G. 2016. Le syndrome d’Ehlers-Danlos de type III. De la physiopathologie à la thérapeutique. J. réadapt. Méd. 36 :32-37.
  23. Pocinki A. 2014. Breaking the Cycle of Chronic Pain, Poor Sleep, Depression, and Fatigue. Retrieved fromhttps://www.ehlers-danlos.com/2014-annual-conference-files/Alan%20Pocinki.pdf
  24. Hakim A, De Wandele I, O’Callaghan C, Pocinki A, Rowe P. 2017. Chronic fatigue in Ehlers-Danlos syndrome – hypermobile type. Am J Med Genet 175C :175-180
  25. Bravo JF. 2016. La dysautonomie dans le syndrome Ehlers-Danlos type III. J. réadapt.Méd. 36 :52-55
  26. Henderson Sr. FC, Austin C, Benzel E, Bolognese P, Ellenbogen R, Francomano CA, Ireton C, Klinge P, Koby M, Long D, Patel S, Singman EL, Voermans NC. 2017. Neurological and spinal manifestations of the Ehlers–Danlos syndromes. Am J Med Genet Part C Semin Med Genet 175C:195–211.
  27. Marié Tanay C. 2015. Etude des apports de la L-Dopa dans le traitement du syndrome d’Ehlers-Danlos
  28. Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, Bloom L, Bowen JM, Brady AF, Burrows NP, Castori M, Cohen H, Colombi M, Demirdas S, De Backer J, De Paepe A, Fournel-Gigleux S, Frank M, Ghali N, Giunta C, Grahame R, Hakim A, Jeunemaitre X, Johnson D, Juul-Kristensen B, Kapferer-Seebacher I, Kazkaz H, Kosho T, Lavallee ME, Levy H, Mendoza-Londono R, Pepin M, Pope FM, Reinstein E, Robert L, Rohrbach M, Sanders L, Sobey GJ, Van Damme T, Vandersteen A, van Mourik C, Voermans N, Wheeldon N, Zschocke J, Tinkle B. 2017. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet Part C Semin Med Genet 175C:8-26.
  29. Francomano C, Bloom L. 2017. The 2017 EDS Classification Your Questions Answered. Retrieved fromhttps://ehlers-danlos.com/wp-content/uploads/QandA-2.pdf
  30. Grahame R. 2016. Le syndrome d’hypermobilité. J.réadapt.Méd. 36 :7-8
  31. Hamonet C. 2011. Conseils pour une bonne utilisation du stimulateur électrique antidouleur TENS dans les syndromes d’Ehlers-Danlos (SED). Retrieved fromhttps://www.ased.fr/files/TENS_UTILISATION.pdf
  32. Engelbert RH, Juul-Kristensen B, Pacey V, de Wandele I, Smeenk S, Woinarosky N, Sabo S, Scheper MC, Russek L, Simmonds JV. 2017. The evidence-based rationale for physical therapy treatment of children, adolescents, and adults diagnosed with joint hypermobility syndrome/hypermobile Ehlers Danlos syndrome. Am J Med Genet Part C Semin Med Genet 175C:158–167.
  33. Chopra P. 2017. Management of complex pain in children and adults with Ehlers Danlos Syndromes. Retrieved fromhttps://www.ehlers-danlos.com/pdf/The-EDS-Society-Pain-presentation-Chopra-2017-S.pdf
  34. Parry J. 2017. Dislocation/Subluxation Management, or ‘I’m Just Popping out for a while. Retrieved fromhttps://www.ehlers-danlos.com/dislocation-subluxation-management/
  35. Eds.info. Fatigue and EDS-H/JHS. Retrieved fromhttps://www.edhs.info/about1-c1ah1
  36. Jamieson-Lega K, Berry R, Brown CA. 2013. A concept analysis of a chronic pain intervention. Pain Res Manag 2013; 18(4):207-2013
  37. De Coster P, Martens L, De Paepe A. 2005. Oral health in prevalent types of Ehlers-Danlos syndromes. Journal of Oral Pathology and Medicine,34,298–307.
  38. Arulanandam S, Tang J, Sandhu G, Birchall M. 2016. Laryngological presentations of Ehlers–Danlos syndrome: case series of nine patients from two London tertiary referral centres. Clinical otolaryngology,42, 860-863.
  39. Weir F, Hatch J, Muus J, Wallace S, Meyer T. 2016. Audiologic Outcomes in Ehlers-Danlos Syndrome in Otology and neurology, 748-752.
  40. Baeza-Velasco C., Bourdon C., Polance-Carrasco R., De jouvencel M., Gely-Nargeot M.C., Gompel A. (2017). Cognitive impairment in women with joint hypermobility syndrome/Ehlers-Danlos syndrome hypermobility type.  Rheumatology international,37,937-939.
  41. Bourdon C, De Jouvencel M, Baeza-Velasco C, Hamonet, C. 2016.Trastornos cognitivos en el sindrome de Ehlers-Danlos. Cuadernos de Neuropsicologia, 10, 72-77.
  42. Metlaine A. 2016. Sommeil et fatigue chez les patients souffrant de syndrome d’Ehlers-Danlos. J.réadapt.Méd. 36 :62-63
  43. Hamonet C, Vienne M, Leroux C, Letinaud MP, Paumier J, Dehecq B, Metlaine A, Brock I, Bird FM. 2016. Manifestations respiratoires dans le syndrome d’Ehlers-Danlos (SED). Nouveaux apports thérapeutiques. J.réadapt.Méd. 36 :56-61.
  44. Grossin D, Daens S. 2018. Le Syndrome d’Ehlers-Danlos et le Syndrome d’Activation Mastocytaire : le SAMED ?

Support Novacombian

If you would like to fund a research project please donate to Novacombian

Click Here to Donate

Contact Us

!
!
!

Please do not submit any Protected Health Information (PHI).

Error!

    Disclaimer: The information provided on this page is for general informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay seeking it because of the information you have read on this website.